Helena Strigård

May 15, 2024

Discover more

Placeholder image for NorthX Biologics Partners to Advance Manufacturing of Retogatein (rhGAD65) for Type 1 Diabetes Toward Commercialization

January 23, 2026

NorthX Biologics Partners to Advance Manufacturing of Retogatein (rhGAD65) for Type 1 Diabetes Toward Commercialization

NorthX Biologics is entering a long term collaboration with Diamyd Medical and APL to support the preparation of retogatein (rhGAD65) for commercial manufacturing. Retogatein is being developed as a therapy aimed at preserving insulin producing cells in people with ...

December 1, 2025

NorthX Biologics achieves milestone GMP certification to manufacture vididencel

Mendus’ lead cell therapy product for acute and chronic myeloid leukemias Matfors, Sweden, 12 01 2025. NorthX Biologics, a leading CDMO and Swedish national innovation hub for advanced biologics, and ...

September 11, 2025

Innovation comes to life through production

Janet Hoogstraate on Sweden’s role in global biomanufacturing Sweden has built a strong foundation in life science, with world-class research environments, advanced infrastructure, and skilled professionals. In a recent interview ...